ClinicalTrials.gg
CompletedNCT06649877Updated Oct 21, 2024

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

A Phase 1 interventional study of MK-6194 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.
  • Registered 1 year 6 months after the study started (first participant enrolled Mar 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think that the average amount of MK-6194 in a person's body over time will be similar when injected into the thigh or abdomen. They also want to learn if it is safe to inject MK-6194 into the abdomen and thigh, and if people tolerate it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has a (BMI) within 18 to 35 kg/m2 and weighs at least 50 kg

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Abdomen Injection

    Participants will receive a single dose of MK-6194 injected into the abdomen.

    Biological: MK-6194

  • Experimental
    Thigh Injection

    Participants will receive a single dose of MK-6194 injected into the thigh.

    Biological: MK-6194

Interventions

  • BiologicalMK-6194

    single injected dose

    Also known as: PT101

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-6194

    Blood samples will be collected to determine the AUC0-Last of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  2. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6194

    Blood samples will be collected to determine the AUC0-Inf of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  3. Maximum Plasma Concentration (Cmax) of MK-6194

    Blood samples will be collected to determine the Cmax of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  4. Time to Maximum Plasma Concentration (Tmax) of MK-6194

    Blood samples will be collected to determine the Tmax of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  5. Apparent Clearance (CL/F) of MK-6194

    Blood samples will be collected to determine the CL/F of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  6. Apparent Terminal Half-life (t1/2) of MK-6194

    Blood samples will be collected to determine the t1/2 of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

  7. Apparent Volume of Distribution (Vz/F) of MK-6194

    Blood samples will be collected to determine the Vz/F of MK-6194.

    Time frame: At designated timepoints (up to approximately 4 weeks postdose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 12 weeks

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 12 weeks

07

Study locations

1 site
  • QPS-MRA, LLC-Early Phase (Site 0001)
    South Miami, Florida 33143, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jul 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 21, 2024
StartActual
Mar 20, 2023
Primary completionActual
Jul 13, 2023
CompletionActual
Jul 13, 2023
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649877
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Mar 20, 2023
Primary completion
Jul 13, 2023
Completion
Jul 13, 2023
Last update
Oct 21, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion